share_log

Arcutis Biotherapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Frazier Life Sciences VIII, L.P.(7.8%),FHM Life Sciences VIII, L.P.(7.8%), etc.

SEC announcement ·  Mar 6 12:44
Summary by Moomoo AI
On March 4, 2024, Frazier Life Sciences VIII, L.P., along with associated entities and individuals, filed an amendment to their Schedule 13D with the SEC, disclosing their ownership stake in Arcutis Biotherapeutics, Inc. The filing indicates that Frazier Life Sciences VIII, L.P. and its general partner entities, as well as James N. Topper and Patrick J. Heron, collectively hold 8,785,284 shares of common stock, representing a 7.8% ownership in the company. The shares are held for investment purposes, and the group may acquire additional shares or dispose of their holdings depending on market conditions and their ongoing evaluation of the business. The filing also details the history of their investment in Arcutis, including purchases of common and preferred stock, and distributions to partners. Additionally, the filing outlines certain agreements, including a lock-up agreement restricting the sale of shares until April 28, 2024, and an Investors' Rights Agreement that allows for registration of shares for resale under certain conditions.
On March 4, 2024, Frazier Life Sciences VIII, L.P., along with associated entities and individuals, filed an amendment to their Schedule 13D with the SEC, disclosing their ownership stake in Arcutis Biotherapeutics, Inc. The filing indicates that Frazier Life Sciences VIII, L.P. and its general partner entities, as well as James N. Topper and Patrick J. Heron, collectively hold 8,785,284 shares of common stock, representing a 7.8% ownership in the company. The shares are held for investment purposes, and the group may acquire additional shares or dispose of their holdings depending on market conditions and their ongoing evaluation of the business. The filing also details the history of their investment in Arcutis, including purchases of common and preferred stock, and distributions to partners. Additionally, the filing outlines certain agreements, including a lock-up agreement restricting the sale of shares until April 28, 2024, and an Investors' Rights Agreement that allows for registration of shares for resale under certain conditions.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more